Exhibit 99.2 Grow with Ginkgo GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Exhibit 99.2 Grow with Ginkgo GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

DIS CL AIMER Disclaimer This confidential presentation (the “presentation”) is being delivered to you by Soaring Eagle Acquisition Corp. (“SRNG”) and Ginkgo Bioworks, Inc. (“Ginkgo”) for use by Ginkgo and SRNG in connection with their proposed business combination and the offering of the securities of the post-business combination company in a private placement (the “Transaction”). This presentation is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in Ginkgo. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of its contents, without the prior consent of Ginkgo is prohibited. By accepting this presentation, each recipient agrees (on behalf of itself and each of its directors, partners, officers, employees, attorneys, financial advisors, agents and representatives (each of the foregoing, a “representative”) agrees: (i) to maintain (and direct its representatives to maintain) the confidentiality of all information that is contained in this presentation and not already in the public domain; and (ii) to return or destroy (and direct its representatives to return or destroy) all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies. Neither this presentation nor any oral statements made in connection with this presentation shall constitute an offer to sell or the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval, in any jurisdiction in connection with the proposed business combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No Representations or Warranties This presentation is for informational purposes only and does not purport to contain all of the information that may be required to evaluate a possible investment decision with respect to Ginkgo. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. No representation or warranty, express or implied, is or will be given by SRNG or Ginkgo or any of their respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation of a possible transaction between SRNG and Ginkgo and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. SRNG and Ginkgo disclaim any duty to update the information contained in this presentation. Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SRNG’s and Ginkgo’s actual results may differ from their expectations, estimates and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, SRNG’s and Ginkgo’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of closing conditions to the Transaction and the timing of the completion of the Transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of SRNG’s registration statement on Form S-1. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the Transaction, which is expected to be filed by Ginkgo with the Securities and Exchange Commission (the “SEC”), and other documents filed by SRNG from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside SRNG’s and Ginkgo’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against SRNG or Ginkgo following the announcement of the Transaction; (2) the inability to complete the Transaction, including due to the inability to concurrently close the business combination and the private placement of common stock or due to failure to obtain approval of the stockholders of SRNG; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals, or delays in completing regulatory reviews, required to complete the Transaction; (4) the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; (5) the inability to recognize the anticipated benefits of the Transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (6) costs related to the Transaction; (7) changes in the applicable laws or regulations; (8) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) the risks described in the Appendix hereto; and (11) other risks and uncertainties indicated from time to time described in SRNG’s registration on Form S-1, including those under “Risk Factors” therein, and in SRNG’s other filings with the SEC. SRNG and Ginkgo caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Neither SRNG nor Ginkgo undertakes or accepts any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Industry and Market Data In this presentation, SRNG and Ginkgo rely on and refer to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo’s management’s estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information. Neither Ginkgo nor SRNG has independently verified the accuracy or completeness of the information provided by the third-party sources. 2DIS CL AIMER Disclaimer This confidential presentation (the “presentation”) is being delivered to you by Soaring Eagle Acquisition Corp. (“SRNG”) and Ginkgo Bioworks, Inc. (“Ginkgo”) for use by Ginkgo and SRNG in connection with their proposed business combination and the offering of the securities of the post-business combination company in a private placement (the “Transaction”). This presentation is for information purposes only and is being provided to you solely in your capacity as a potential investor in considering an investment in Ginkgo. Any reproduction or distribution of this presentation, in whole or in part, or the disclosure of its contents, without the prior consent of Ginkgo is prohibited. By accepting this presentation, each recipient agrees (on behalf of itself and each of its directors, partners, officers, employees, attorneys, financial advisors, agents and representatives (each of the foregoing, a “representative”) agrees: (i) to maintain (and direct its representatives to maintain) the confidentiality of all information that is contained in this presentation and not already in the public domain; and (ii) to return or destroy (and direct its representatives to return or destroy) all copies of this presentation or portions thereof in its possession following the request for the return or destruction of such copies. Neither this presentation nor any oral statements made in connection with this presentation shall constitute an offer to sell or the solicitation of an offer to buy any securities, or the solicitation of any proxy, vote, consent or approval, in any jurisdiction in connection with the proposed business combination, nor shall there be any sale of securities in any jurisdiction in which the offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction where such distribution or use would be contrary to local law or regulation. No Representations or Warranties This presentation is for informational purposes only and does not purport to contain all of the information that may be required to evaluate a possible investment decision with respect to Ginkgo. The recipient agrees and acknowledges that this presentation is not intended to form the basis of any investment decision by the recipient and does not constitute investment, tax or legal advice. No representation or warranty, express or implied, is or will be given by SRNG or Ginkgo or any of their respective affiliates, directors, officers, employees or advisers or any other person as to the accuracy or completeness of the information in this presentation or any other written, oral or other communications transmitted or otherwise made available to any party in the course of its evaluation of a possible transaction between SRNG and Ginkgo and no responsibility or liability whatsoever is accepted for the accuracy or sufficiency thereof or for any errors, omissions or misstatements, negligent or otherwise, relating thereto. The recipient also acknowledges and agrees that the information contained in this presentation is preliminary in nature and is subject to change, and any such changes may be material. SRNG and Ginkgo disclaim any duty to update the information contained in this presentation. Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. SRNG’s and Ginkgo’s actual results may differ from their expectations, estimates and projections, and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, SRNG’s and Ginkgo’s expectations with respect to future performance and anticipated financial impacts of the Transaction, the satisfaction of closing conditions to the Transaction and the timing of the completion of the Transaction. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. You should carefully consider the risks and uncertainties described in the “Risk Factors” section of SRNG’s registration statement on Form S-1. In addition, there will be risks and uncertainties described in the proxy statement/prospectus on Form S-4 relating to the Transaction, which is expected to be filed by Ginkgo with the Securities and Exchange Commission (the “SEC”), and other documents filed by SRNG from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Most of these factors are outside SRNG’s and Ginkgo’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against SRNG or Ginkgo following the announcement of the Transaction; (2) the inability to complete the Transaction, including due to the inability to concurrently close the business combination and the private placement of common stock or due to failure to obtain approval of the stockholders of SRNG; (3) delays in obtaining, adverse conditions contained in, or the inability to obtain necessary regulatory approvals, or delays in completing regulatory reviews, required to complete the Transaction; (4) the risk that the Transaction disrupts current plans and operations as a result of the announcement and consummation of the Transaction; (5) the inability to recognize the anticipated benefits of the Transaction, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain key employees; (6) costs related to the Transaction; (7) changes in the applicable laws or regulations; (8) the possibility that the combined company may be adversely affected by other economic, business, and/or competitive factors; (9) the impact of the global COVID-19 pandemic; (10) the risks described in the Appendix hereto; and (11) other risks and uncertainties indicated from time to time described in SRNG’s registration on Form S-1, including those under “Risk Factors” therein, and in SRNG’s other filings with the SEC. SRNG and Ginkgo caution that the foregoing list of factors is not exclusive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Neither SRNG nor Ginkgo undertakes or accepts any obligation to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. Industry and Market Data In this presentation, SRNG and Ginkgo rely on and refer to certain information and statistics regarding the markets and industries in which Ginkgo competes. Such information and statistics are based on Ginkgo’s management’s estimates and/or obtained from third-party sources, including reports by market research firms and company filings. While Ginkgo believes such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the indicated information. Neither Ginkgo nor SRNG has independently verified the accuracy or completeness of the information provided by the third-party sources. 2

DIS CL AIMER Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and SRNG’s and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but SRNG and Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Private Placement The securities to which this presentation relate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that SRNG intends to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense. Financial Information This presentation contains certain estimated preliminary financial results and key operating metrics for the year ended December 31, 2020, and the historical financial information with respect to Ginkgo contained in this presentation has been taken from or prepared based on historical financial statements of Ginkgo, including unaudited financial statements for its fiscal year ended December 31, 2020. This information is preliminary and subject to adjustment in connection with the completion of the audit for the fiscal year ended December 31, 2020. As such, Ginkgo’s actual results and financial condition as reflected in the financial statements that will be included in the proxy statement/prospectus on Form S-4 for the proposed Transaction may be adjusted or presented differently from the historical financial information herein, and the variations could be material. Non-GAAP Financial Measures Certain of the financial measures included in this presentation, including Foundry Billable Revenue, Foundry Billable Revenue Growth, Net Present Value (NPV) and Adjusted EBITDA, have not been prepared in accordance with general accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures (including on a forward-looking basis) because it believes they provide an additional tool for investors to use in evaluating the financial performance and prospects of Ginkgo or any successor entity in the Transaction. These non-GAAP financial measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the Appendix for a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures. Note however, that to the extent forward-looking non-GAAP financial measures are provided herein, they are not reconciled to comparable forward-looking GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Use of Projections This presentation also contains certain financial forecasts, including projected Foundry Billable Revenue, Foundry Billable Revenue Growth, Foundry Revenue (GAAP), Biosecurity Revenue, Total GAAP Revenue, Adjusted EBITDA and CapEx. Neither SRNG’s nor Ginkgo’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and, accordingly, neither of them have expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. In this presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Projections are inherently uncertain due to a number of factors outside of SRNG’s or Ginkgo’s control. While all financial projections, estimates and targets are necessarily speculative, SRNG and Ginkgo believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. Participation in Solicitation SRNG and Ginkgo and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies of SRNG’s shareholders in connection with the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of SRNG’s directors and officers in SRNG’s filings with the SEC, including SRNG’s registration statement on Form S-1, which was originally filed with the SEC on December 23, 2020. To the extent that holdings of SRNG’s securities have changed from the amounts reported in SRNG’s registration statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SRNG’s shareholders in connection with the proposed Transaction will be set forth in the proxy statement/prospectus on Form S-4 for the proposed Transaction, which is expected to be filed by SRNG with the SEC. Investors and security holders of SRNG and Ginkgo are urged to read the proxy statement/prospectus and other relevant documents that will be filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed Transaction. Investors and security holders will be able to obtain free copies of the proxy statement and other documents containing important information about SRNG and Ginkgo through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by SRNG can be obtained free of charge by directing a written request to SRNG, 955 Fifth Avenue, New York, NY 10075. 3DIS CL AIMER Trademarks This presentation may contain trademarks, service marks, trade names and copyrights of other companies, which are the property of their respective owners, and SRNG’s and Ginkgo’s use thereof does not imply an affiliation with, or endorsement by, the owners of such trademarks, service marks, trade names and copyrights. Solely for convenience, some of the trademarks, service marks, trade names and copyrights referred to in this presentation may be listed without the TM, © or ® symbols, but SRNG and Ginkgo will assert, to the fullest extent under applicable law, the rights of the applicable owners, if any, to these trademarks, service marks, trade names and copyrights. Private Placement The securities to which this presentation relate have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any other jurisdiction. This presentation relates to securities that SRNG intends to offer in reliance on exemptions from the registration requirements of the Securities Act and other applicable laws. These exemptions apply to offers and sales of securities that do not involve a public offering. The securities have not been approved or recommended by any federal, state or foreign securities authorities, nor have any of these authorities passed upon the merits of this offering or determined that this presentation is accurate or complete. Any representation to the contrary is a criminal offense. Financial Information This presentation contains certain estimated preliminary financial results and key operating metrics for the year ended December 31, 2020, and the historical financial information with respect to Ginkgo contained in this presentation has been taken from or prepared based on historical financial statements of Ginkgo, including unaudited financial statements for its fiscal year ended December 31, 2020. This information is preliminary and subject to adjustment in connection with the completion of the audit for the fiscal year ended December 31, 2020. As such, Ginkgo’s actual results and financial condition as reflected in the financial statements that will be included in the proxy statement/prospectus on Form S-4 for the proposed Transaction may be adjusted or presented differently from the historical financial information herein, and the variations could be material. Non-GAAP Financial Measures Certain of the financial measures included in this presentation, including Foundry Billable Revenue, Foundry Billable Revenue Growth, Net Present Value (NPV) and Adjusted EBITDA, have not been prepared in accordance with general accepted accounting principles (“GAAP”), and constitute “non-GAAP financial measures” as defined by the SEC. Ginkgo has included these non-GAAP financial measures (including on a forward-looking basis) because it believes they provide an additional tool for investors to use in evaluating the financial performance and prospects of Ginkgo or any successor entity in the Transaction. These non-GAAP financial measures should not be considered in isolation from, or as an alternative to, financial measures determined in accordance with GAAP. In addition, these non-GAAP financial measures may differ from non-GAAP financial measures with comparable names used by other companies. See the Appendix for a description of these non-GAAP financial measures and a reconciliation of the historic measures to Ginkgo’s most comparable GAAP financial measures. Note however, that to the extent forward-looking non-GAAP financial measures are provided herein, they are not reconciled to comparable forward-looking GAAP measures due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation. Use of Projections This presentation also contains certain financial forecasts, including projected Foundry Billable Revenue, Foundry Billable Revenue Growth, Foundry Revenue (GAAP), Biosecurity Revenue, Total GAAP Revenue, Adjusted EBITDA and CapEx. Neither SRNG’s nor Ginkgo’s independent auditors have studied, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and, accordingly, neither of them have expressed an opinion or provided any other form of assurance with respect thereto for the purpose of this presentation. These projections are for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. In this presentation, certain of the above-mentioned projected information has been provided for purposes of providing comparisons with historical data. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Projections are inherently uncertain due to a number of factors outside of SRNG’s or Ginkgo’s control. While all financial projections, estimates and targets are necessarily speculative, SRNG and Ginkgo believe that the preparation of prospective financial information involves increasingly higher levels of uncertainty the further out the projection, estimate or target extends from the date of preparation. Accordingly, there can be no assurance that the prospective results are indicative of future performance of the combined company after the Transaction or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. Participation in Solicitation SRNG and Ginkgo and their respective directors and executive officers may be deemed under SEC rules to be participants in the solicitation of proxies of SRNG’s shareholders in connection with the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of SRNG’s directors and officers in SRNG’s filings with the SEC, including SRNG’s registration statement on Form S-1, which was originally filed with the SEC on December 23, 2020. To the extent that holdings of SRNG’s securities have changed from the amounts reported in SRNG’s registration statement on Form S-1, such changes have been or will be reflected on Statements of Change in Ownership on Form 4 filed with the SEC. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to SRNG’s shareholders in connection with the proposed Transaction will be set forth in the proxy statement/prospectus on Form S-4 for the proposed Transaction, which is expected to be filed by SRNG with the SEC. Investors and security holders of SRNG and Ginkgo are urged to read the proxy statement/prospectus and other relevant documents that will be filed with the SEC carefully and in their entirety when they become available because they will contain important information about the proposed Transaction. Investors and security holders will be able to obtain free copies of the proxy statement and other documents containing important information about SRNG and Ginkgo through the website maintained by the SEC at www.sec.gov. Copies of the documents filed with the SEC by SRNG can be obtained free of charge by directing a written request to SRNG, 955 Fifth Avenue, New York, NY 10075. 3

Transaction Overview (4) Transaction Summary Pro Forma Enterprise Value ($M, except per share amount) • Ginkgo Bioworks has entered into a definitive agreement to merge with Soaring Eagle Acquisition Corp. (Nasdaq:SRNG), valuing Ginkgo at an enterprise value of $15 billion Share Price $10.00 • All-primary transaction will result in gross proceeds of $2.5 billion, through a combination of: (5) (1) Pro Forma Shares Outstanding (M) 1,780.3 – SRNG’s $1,725 million cash in trust – $775 million of committed PIPE financing at $10 / share including anchor commitments from Baillie P OS T -T R ANS AC T ION EQUIT Y VALUE $17,803 Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management) and a $75 million investment by the Soaring Eagle sponsor group (6) (-) Cash ($2,639) – 30% of sponsor promote converted to earnout; additionally, Ginkgo shareholders will be granted up to 180M earnout shares (11% seller earnout) vesting between $12.50 and $20/share PRO FORM A ENT ERPRISE VALUE $15,164 • Closing expected in Q3 2021 (7) Illustrative Pro Forma Ownership Illustrative Sources & Uses ($M) 2% 4% Ginkgo Bioworks Sources Uses 10% (1) (2) SRNG Cash Held in Trust $1,725 Consideration Shares $15,000 SRNG Shareholders (1) Cash Proceeds from PIPE 775 Cash to Balance Sheet 2,365 (2) (3) Parties’ Transaction Fees Rollover by Equity Holders 15,000 135 PIPE Shareholders 84% T O TA L $17,500 $17,500 T O TA L Sponsor Shares (1) Assumes no redemptions (2) Inclusive of value attributable to all outstanding equity awards other than those subject to unsatisfied service-based vesting conditions; includes aggregate exercise prices of outstanding options and warrants (3) Represents estimated transaction expenses based on a $775M PIPE as of 5/6/2021 (4) Enterprise Value calculation excludes $18M in financing lease liabilities as of 12/31/2020 (5) Includes 1.5B Consideration Shares to Ginkgo, 172.5M shares to SRNG shareholders, 77.5M shares to PIPE shareholders and 30.2M shares retained by SRNG sponsor (inclusive of 150,000 shares transferred to SRNG’s independent directors) (6) Includes Ginkgo cash balance of $274M as of 4/30/2021; excludes restricted cash and any disbursements that may be made from US DFC loan under negotiation (7) Assumes no redemptions and excludes SRNG / Ginkgo earn-out shares and SRNG warrants 4 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Transaction Overview (4) Transaction Summary Pro Forma Enterprise Value ($M, except per share amount) • Ginkgo Bioworks has entered into a definitive agreement to merge with Soaring Eagle Acquisition Corp. (Nasdaq:SRNG), valuing Ginkgo at an enterprise value of $15 billion Share Price $10.00 • All-primary transaction will result in gross proceeds of $2.5 billion, through a combination of: (5) (1) Pro Forma Shares Outstanding (M) 1,780.3 – SRNG’s $1,725 million cash in trust – $775 million of committed PIPE financing at $10 / share including anchor commitments from Baillie P OS T -T R ANS AC T ION EQUIT Y VALUE $17,803 Gifford, Putnam Investments, and funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management) and a $75 million investment by the Soaring Eagle sponsor group (6) (-) Cash ($2,639) – 30% of sponsor promote converted to earnout; additionally, Ginkgo shareholders will be granted up to 180M earnout shares (11% seller earnout) vesting between $12.50 and $20/share PRO FORM A ENT ERPRISE VALUE $15,164 • Closing expected in Q3 2021 (7) Illustrative Pro Forma Ownership Illustrative Sources & Uses ($M) 2% 4% Ginkgo Bioworks Sources Uses 10% (1) (2) SRNG Cash Held in Trust $1,725 Consideration Shares $15,000 SRNG Shareholders (1) Cash Proceeds from PIPE 775 Cash to Balance Sheet 2,365 (2) (3) Parties’ Transaction Fees Rollover by Equity Holders 15,000 135 PIPE Shareholders 84% T O TA L $17,500 $17,500 T O TA L Sponsor Shares (1) Assumes no redemptions (2) Inclusive of value attributable to all outstanding equity awards other than those subject to unsatisfied service-based vesting conditions; includes aggregate exercise prices of outstanding options and warrants (3) Represents estimated transaction expenses based on a $775M PIPE as of 5/6/2021 (4) Enterprise Value calculation excludes $18M in financing lease liabilities as of 12/31/2020 (5) Includes 1.5B Consideration Shares to Ginkgo, 172.5M shares to SRNG shareholders, 77.5M shares to PIPE shareholders and 30.2M shares retained by SRNG sponsor (inclusive of 150,000 shares transferred to SRNG’s independent directors) (6) Includes Ginkgo cash balance of $274M as of 4/30/2021; excludes restricted cash and any disbursements that may be made from US DFC loan under negotiation (7) Assumes no redemptions and excludes SRNG / Ginkgo earn-out shares and SRNG warrants 4 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Our Mission Make biology easier to engineer 5 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Our Mission Make biology easier to engineer 5 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

2006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” The founders have been working together for nearly 20 years on this vision of synthetic biology 2019 6 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 12006 Tom Knight with his master’s MIT,1972 thesis, a “minicomputer” The founders have been working together for nearly 20 years on this vision of synthetic biology 2019 6 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

LEARN MORE LEARN MORE We can program cells (DNA) like we program computers (code) 7 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1LEARN MORE LEARN MORE We can program cells (DNA) like we program computers (code) 7 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Cell programming is increasingly impacting our lives Ginkgo’s work to close raw material gaps in the mRNA vaccine supply chain was recently featured on 60 Minutes Vaccines are developed and manufactured using cell programming tools 8 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Cell programming is increasingly impacting our lives Ginkgo’s work to close raw material gaps in the mRNA vaccine supply chain was recently featured on 60 Minutes Vaccines are developed and manufactured using cell programming tools 8 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Cell programming is addressing our most challenging environmental and social issues Food & Agriculture Industrials & Environment Consumer & Technology Pharma & Biotech Nucleic acid Wastewater Renewable Animal protein Sugar Plant extracts: Haircare and Antibody vaccine remediation chemicals replacement reduction flavors, skincare therapeutic production fragrances, proteins development cannabinoids Textiles and Antibiotic Sustainable Brewing & Fertilizer Microbiome PFAS dyes Skin discovery and building baking reduction therapeutics degradation microbiome manufacturing materials (protection Electronic Carbon Pest control Animal feed and Gene and cell and beauty) coatings sequestration aquaculture therapies and we’re just getting started… Read “Anatomy of an Read “Redesigning Read “Ingredient Read “Microscopic Underground Wildfire” on Grow the Banana” on Grow Revolution” on Grow Doctors” on Grow GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Cell programming is addressing our most challenging environmental and social issues Food & Agriculture Industrials & Environment Consumer & Technology Pharma & Biotech Nucleic acid Wastewater Renewable Animal protein Sugar Plant extracts: Haircare and Antibody vaccine remediation chemicals replacement reduction flavors, skincare therapeutic production fragrances, proteins development cannabinoids Textiles and Antibiotic Sustainable Brewing & Fertilizer Microbiome PFAS dyes Skin discovery and building baking reduction therapeutics degradation microbiome manufacturing materials (protection Electronic Carbon Pest control Animal feed and Gene and cell and beauty) coatings sequestration aquaculture therapies and we’re just getting started… Read “Anatomy of an Read “Redesigning Read “Ingredient Read “Microscopic Underground Wildfire” on Grow the Banana” on Grow Revolution” on Grow Doctors” on Grow GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

PROGRAM LAYER Ginkgo provides program management and technical execution to product companies across all industries LEARN MORE PLATFORM LAYER Ginkgo is building the leading horizontal platform for Ginkgo is the interface cell programming across all industries between a series of complex technologies and a customer spec LEARN MORE TECHNOLOGY LAYER Ginkgo integrates standard hardware and wraps it in proprietary software and automation 10 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1PROGRAM LAYER Ginkgo provides program management and technical execution to product companies across all industries LEARN MORE PLATFORM LAYER Ginkgo is building the leading horizontal platform for Ginkgo is the interface cell programming across all industries between a series of complex technologies and a customer spec LEARN MORE TECHNOLOGY LAYER Ginkgo integrates standard hardware and wraps it in proprietary software and automation 10 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We program cells for our customers so they can develop new products 11 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We program cells for our customers so they can develop new products 11 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY Customers run their programs on Ginkgo’s platform to drive business value % 303 300 Ginkgo partnered with Motif to develop more delicious and IMPROVEMENT OVER PROTEINS UNMODIFIED sustainable food. SOURCED STRAINS In just 1 year, 6 prototype strains were developed, and product samples were produced for benchmarking and early application testing. Improved variants were designed, built and validated over the next 9 months. The strain’s performance exceeded Motif’s specifications by >70%. Q4 Q1 Q2 Q3 1 YEAR LATER ITERATIVE STRAIN IDENTIFY POTENTIAL SCREEN FOR BEST STRAIN ENGINEERING & PROTOTYPE STRAINS CONSTRUCTION & TESTING PROTEINS CANDIDATE PROTEIN PATHWAY BALANCING READY Sequence Similarity Network PROTOTYPE 12 Strain Strain Strain Percent Improvement over Seed Protein Percent Improvement over Unmodified Strains Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY Customers run their programs on Ginkgo’s platform to drive business value % 303 300 Ginkgo partnered with Motif to develop more delicious and IMPROVEMENT OVER PROTEINS UNMODIFIED sustainable food. SOURCED STRAINS In just 1 year, 6 prototype strains were developed, and product samples were produced for benchmarking and early application testing. Improved variants were designed, built and validated over the next 9 months. The strain’s performance exceeded Motif’s specifications by >70%. Q4 Q1 Q2 Q3 1 YEAR LATER ITERATIVE STRAIN IDENTIFY POTENTIAL SCREEN FOR BEST STRAIN ENGINEERING & PROTOTYPE STRAINS CONSTRUCTION & TESTING PROTEINS CANDIDATE PROTEIN PATHWAY BALANCING READY Sequence Similarity Network PROTOTYPE 12 Strain Strain Strain Percent Improvement over Seed Protein Percent Improvement over Unmodified Strains Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

1313

Ginkgo is [a] valuable partner Ginkgo is critical to our success and Ginkgo is addressing a foundational providing services to our R&D group development of synbio solutions needed for us challenge that enables us to scale our that could not otherwise be to be successful. antibody discovery platform. Prior to done internally. C E O, partnering, we had screened 173 antibodies on I NDU S T R I AL S M A N A GE R, our own. Together, we are planning an initial P HA R MA screen of 5,000 antibodies and are jointly developing tools to screen tens of thousands at dramatically lower costs. Our collaboration has been successful in large CO -FOUNDER AND CEO, part because the Ginkgo team is thoughtful, P HA R MA creative, communicative, and willing to The engagement of Ginkgo as iterate as more data becomes available. As we a partner was absolutely grow, we hope to foster a similar culture. unprecedented, as if we were CHIEF BUSINE S S OFFICER, a single company working P HA R MA Ginkgo is opening new avenues for towards a single goal. research programs. Early exploratory D IR E C T OR , work, but critically important to support our CONSUMER / FOOD / T ECH pipeline. We highly value the Ginkgo relationship and the BUSINE S S UNI T HE AD, window it provides into synthetic biology as an P HA R MA industry and national capability. V P, IN T ELLIGENCE / DEFENSE Our collaboration with Ginkgo is a key pillar to our company strategy, Ginkgo developed a process to give us a therefore, the positive impact competitive advantage. can not be overstated. Ginkgo is a key enabler of scale up. D IR E C T OR , VP S OURCING, C O O, CONSUMER / FOOD / T ECH P HA R MA CONSUMER / FOOD / T ECH 14 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Ginkgo is [a] valuable partner Ginkgo is critical to our success and Ginkgo is addressing a foundational providing services to our R&D group development of synbio solutions needed for us challenge that enables us to scale our that could not otherwise be to be successful. antibody discovery platform. Prior to done internally. C E O, partnering, we had screened 173 antibodies on I NDU S T R I AL S M A N A GE R, our own. Together, we are planning an initial P HA R MA screen of 5,000 antibodies and are jointly developing tools to screen tens of thousands at dramatically lower costs. Our collaboration has been successful in large CO -FOUNDER AND CEO, part because the Ginkgo team is thoughtful, P HA R MA creative, communicative, and willing to The engagement of Ginkgo as iterate as more data becomes available. As we a partner was absolutely grow, we hope to foster a similar culture. unprecedented, as if we were CHIEF BUSINE S S OFFICER, a single company working P HA R MA Ginkgo is opening new avenues for towards a single goal. research programs. Early exploratory D IR E C T OR , work, but critically important to support our CONSUMER / FOOD / T ECH pipeline. We highly value the Ginkgo relationship and the BUSINE S S UNI T HE AD, window it provides into synthetic biology as an P HA R MA industry and national capability. V P, IN T ELLIGENCE / DEFENSE Our collaboration with Ginkgo is a key pillar to our company strategy, Ginkgo developed a process to give us a therefore, the positive impact competitive advantage. can not be overstated. Ginkgo is a key enabler of scale up. D IR E C T OR , VP S OURCING, C O O, CONSUMER / FOOD / T ECH P HA R MA CONSUMER / FOOD / T ECH 14 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Combining an industry-defining founding team with proven executives who have built iconic public companies Founding team has been working together for nearly 20 years Soaring Eagle brings a track record of success in SPACs Harry Sloan Jeff Sagansky Eli Baker Reshma Shetty Jason Kelly CEO, Chairman Partner President, CFO COO CEO Arie Belldegrun with Founder, Fmr CEO/Chairman, Kite Pharma Founder, Chairman, Allogene Barry Canton Austin Che Tom Knight CTO Strategy DNA Hacker With long-term support from a deeply experienced, industry-leading independent board Marijn Dekkers Christian Henry Shyam Sankar Chairman, Governance/Nominating Chair Audit Committee Chair Compensation Committee Chair Board member since 2019 Board member since 2016 Board member since 2016 Fmr Chairman, Unilever (NYSE:UL) President/CEO, PacBio (Nasdaq:PACB) COO, Palantir (NYSE: PLTR) Fmr CEO, Bayer (XTRA:BAYN) Fmr CFO/CCO, Illumina (Nasdaq:ILMN) Fmr CEO, Thermo Fisher (NYSE:TMO) 15 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Combining an industry-defining founding team with proven executives who have built iconic public companies Founding team has been working together for nearly 20 years Soaring Eagle brings a track record of success in SPACs Harry Sloan Jeff Sagansky Eli Baker Reshma Shetty Jason Kelly CEO, Chairman Partner President, CFO COO CEO Arie Belldegrun with Founder, Fmr CEO/Chairman, Kite Pharma Founder, Chairman, Allogene Barry Canton Austin Che Tom Knight CTO Strategy DNA Hacker With long-term support from a deeply experienced, industry-leading independent board Marijn Dekkers Christian Henry Shyam Sankar Chairman, Governance/Nominating Chair Audit Committee Chair Compensation Committee Chair Board member since 2019 Board member since 2016 Board member since 2016 Fmr Chairman, Unilever (NYSE:UL) President/CEO, PacBio (Nasdaq:PACB) COO, Palantir (NYSE: PLTR) Fmr CEO, Bayer (XTRA:BAYN) Fmr CFO/CCO, Illumina (Nasdaq:ILMN) Fmr CEO, Thermo Fisher (NYSE:TMO) 15 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying Each new program drives We believe Ginkgo’s Each new program adds technology can be used platform improvements, ecosystem of services will predictable near-term to create applications leading to more demand. make us the obvious revenue from usage fees across all physical goods partner in the enormous, and provides Ginkgo industries. Ginkgo is the and largely untapped, upside through value first horizontal platform in market for cell share. this industry, supporting programming. all end markets. 16 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying Each new program drives We believe Ginkgo’s Each new program adds technology can be used platform improvements, ecosystem of services will predictable near-term to create applications leading to more demand. make us the obvious revenue from usage fees across all physical goods partner in the enormous, and provides Ginkgo industries. Ginkgo is the and largely untapped, upside through value first horizontal platform in market for cell share. this industry, supporting programming. all end markets. 16 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying technology can be used to create applications across all physical goods industries. Ginkgo is the first horizontal platform in this industry, supporting all end markets. 17 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers The same underlying technology can be used to create applications across all physical goods industries. Ginkgo is the first horizontal platform in this industry, supporting all end markets. 17 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

The promise and power of biology has never been more apparent 1 YEAR LATER: MARCH 2021 APRIL 2019 11 MONTHS L ATER: MARCH 2020 “...permits the manufacture of all manner of things “Planet earth is shutting down… desperate “Now we have entered…a life-science which used to be hard, even impossible, to make: governments are...handing out trillions of revolution. Children who study digital pharmaceuticals, fuels, fabrics, foods, and dollars in aid and loan guarantees” coding will be joined by those who study fragrances can all be built molecule by molecule.” genetic code.” READ MORE READ MORE 18 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1The promise and power of biology has never been more apparent 1 YEAR LATER: MARCH 2021 APRIL 2019 11 MONTHS L ATER: MARCH 2020 “...permits the manufacture of all manner of things “Planet earth is shutting down… desperate “Now we have entered…a life-science which used to be hard, even impossible, to make: governments are...handing out trillions of revolution. Children who study digital pharmaceuticals, fuels, fabrics, foods, and dollars in aid and loan guarantees” coding will be joined by those who study fragrances can all be built molecule by molecule.” genetic code.” READ MORE READ MORE 18 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

R&D spending alone accounts for nearly $40B in untapped demand Existing market for cell engineering lab operations ($B) $60 $58B Cell Engineering Labor Cell Engineering Tools $48B $50 Our scale $22 dramatically reduces costs $40B $40 $18 $33B This market represents $15 $28B $30 over 20,000+ potential $12 (1) new cell programs $10 We bring $20 $36 efficiency to $30 scientists at the $25 bench $21 $10 $17 $0 2019 2020E 2021E 2022E 2023E Source: Piper Sandler Research (1) Assumes approximately $2M annual expense per program, in line with current average annual spend per program at Ginkgo 19 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1R&D spending alone accounts for nearly $40B in untapped demand Existing market for cell engineering lab operations ($B) $60 $58B Cell Engineering Labor Cell Engineering Tools $48B $50 Our scale $22 dramatically reduces costs $40B $40 $18 $33B This market represents $15 $28B $30 over 20,000+ potential $12 (1) new cell programs $10 We bring $20 $36 efficiency to $30 scientists at the $25 bench $21 $10 $17 $0 2019 2020E 2021E 2022E 2023E Source: Piper Sandler Research (1) Assumes approximately $2M annual expense per program, in line with current average annual spend per program at Ginkgo 19 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

$2 to $4 trillion emerging market for bioengineered products Annual Direct Economic Impact By Domain 2030—2040 (partial estimate) $1.2T $1.2T High Estimate Low Estimate Programming + significant secondary effects not measured biology is to the physical world what $700B programming computers is to the information economy $300B $300B $500B $800B $200B $200B $100B Food & Materials & Health Consumer Other Agriculture Energy Source: McKinsey Global Institute; The Bio Revolution: Innovations transforming economies, societies, and our lives (May 13, 2020) Note: these estimates reflect the estimated biotechnology penetration of these end-markets 20 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1$2 to $4 trillion emerging market for bioengineered products Annual Direct Economic Impact By Domain 2030—2040 (partial estimate) $1.2T $1.2T High Estimate Low Estimate Programming + significant secondary effects not measured biology is to the physical world what $700B programming computers is to the information economy $300B $300B $500B $800B $200B $200B $100B Food & Materials & Health Consumer Other Agriculture Energy Source: McKinsey Global Institute; The Bio Revolution: Innovations transforming economies, societies, and our lives (May 13, 2020) Note: these estimates reflect the estimated biotechnology penetration of these end-markets 20 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program drives platform improvements, leading to more demand. 21 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program drives platform improvements, leading to more demand. 21 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Over 70 major customer programs across diverse industries have run on our platform = DIVERSIFIED PLATFORM Cumulative Major 3rd Party Programs Can respond rapidly to emerging opportunities and global threats 80 + PHARMA & BIOTECH Mammalian capabilities & PRE-2015: GOVERNMENT PROGRAMS Synlogic partnership First 5+ years of technology building 60 funded through non-dilutive government programs (DARPA, SBIR, etc.) + FOOD & NUTRITION Motif (Louis Dreyfus and Fonterra) launches portfolio of animal-free protein programs + AGRICULTURE Selection by Bayer for 40 agriculture JV after significant industry vetting + INDUSTRIAL & ENVIRONMENT Experience in flavors & fragrances enabled expansion into industrial chemicals 20 CONSUMER & TECHNOLOGY Early experimentation making fine chemicals for flavors & fragrances 0 2015 2016 2017 2018 2019 2020 Consumer & Technology Industrial & Environment Agriculture Food & Nutrition Pharma & Biotech Government & Defense Note: “Major” programs exclude proof of concept work and ancillary projects and typically have at least $500K actual / expected development costs on behalf of a customer 22 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Over 70 major customer programs across diverse industries have run on our platform = DIVERSIFIED PLATFORM Cumulative Major 3rd Party Programs Can respond rapidly to emerging opportunities and global threats 80 + PHARMA & BIOTECH Mammalian capabilities & PRE-2015: GOVERNMENT PROGRAMS Synlogic partnership First 5+ years of technology building 60 funded through non-dilutive government programs (DARPA, SBIR, etc.) + FOOD & NUTRITION Motif (Louis Dreyfus and Fonterra) launches portfolio of animal-free protein programs + AGRICULTURE Selection by Bayer for 40 agriculture JV after significant industry vetting + INDUSTRIAL & ENVIRONMENT Experience in flavors & fragrances enabled expansion into industrial chemicals 20 CONSUMER & TECHNOLOGY Early experimentation making fine chemicals for flavors & fragrances 0 2015 2016 2017 2018 2019 2020 Consumer & Technology Industrial & Environment Agriculture Food & Nutrition Pharma & Biotech Government & Defense Note: “Major” programs exclude proof of concept work and ancillary projects and typically have at least $500K actual / expected development costs on behalf of a customer 22 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Market defining customers have validated the platform across a wide range of end markets Industrials CONSUMER & TECH INDUSTRIALS & ENVIRONMENT AGRICULTURE FOOD & NUTRITION PHARMA & BIOTECH Fragrances Commodities & Specialty Chemicals Fertilizers & Crop Animal-free proteins Microbiome Therapeutics (G4, G41, G53) (G15, G24, G48, G51, G90, G101, G116, Enhancement (G114, G121, G122, G128, G136, G162) (G40, G83, G139, G143, G147, G150, G152) Cannabinoids G127, G134, G142, G159) (G50, G81, G133) Flavors & Sweeteners Biologics & Gene Therapy (G102, G123) Textiles Crop Protection (G49, G56, G125, G174) (G66, G70, G115, G185) Insect Repellent (G36) (G99, G119, G132, G151, G163, Nutrition Antibiotics & APIs (G166) Environment G165) (G35, G69, G109) (G21, G67, G72, G86, G111) High-tech electronics (G131, G138, G145, G153, G164, G171) Animal Feed Brewing & Baking COVID Vaccines & Therapeutics (G37, G43) (G16, G68, G71, G146) (G52, G95, G97) (G155, G157, G158, G163, G165, G169, G170) 23 Note: Reflects a portion of current / completed programs; program codes have been anonymized GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Market defining customers have validated the platform across a wide range of end markets Industrials CONSUMER & TECH INDUSTRIALS & ENVIRONMENT AGRICULTURE FOOD & NUTRITION PHARMA & BIOTECH Fragrances Commodities & Specialty Chemicals Fertilizers & Crop Animal-free proteins Microbiome Therapeutics (G4, G41, G53) (G15, G24, G48, G51, G90, G101, G116, Enhancement (G114, G121, G122, G128, G136, G162) (G40, G83, G139, G143, G147, G150, G152) Cannabinoids G127, G134, G142, G159) (G50, G81, G133) Flavors & Sweeteners Biologics & Gene Therapy (G102, G123) Textiles Crop Protection (G49, G56, G125, G174) (G66, G70, G115, G185) Insect Repellent (G36) (G99, G119, G132, G151, G163, Nutrition Antibiotics & APIs (G166) Environment G165) (G35, G69, G109) (G21, G67, G72, G86, G111) High-tech electronics (G131, G138, G145, G153, G164, G171) Animal Feed Brewing & Baking COVID Vaccines & Therapeutics (G37, G43) (G16, G68, G71, G146) (G52, G95, G97) (G155, G157, G158, G163, G165, G169, G170) 23 Note: Reflects a portion of current / completed programs; program codes have been anonymized GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

The Foundry - Ginkgo’s physical infrastructure - drives a strong scale economic BW5 Lab-scale automation and significantly increased NGS capacity BW4 Added mammalian cell engineering capabilities BW3 Created scale modules by function KNIGHT’S LAW – our scale theory (e.g. DNA synthesis, -omics, BW2 sequencing, fermentation, etc.) “The cost to genetically engineer a cell decreases by 50% and the number of designs tested increases by BW1 3X+ per year in Ginkgo’s automated cell programming Early stages of building higher scale workflows and testing foundries.” automated techniques 24 2012 2016 2018 2019 2020 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1The Foundry - Ginkgo’s physical infrastructure - drives a strong scale economic BW5 Lab-scale automation and significantly increased NGS capacity BW4 Added mammalian cell engineering capabilities BW3 Created scale modules by function KNIGHT’S LAW – our scale theory (e.g. DNA synthesis, -omics, BW2 sequencing, fermentation, etc.) “The cost to genetically engineer a cell decreases by 50% and the number of designs tested increases by BW1 3X+ per year in Ginkgo’s automated cell programming Early stages of building higher scale workflows and testing foundries.” automated techniques 24 2012 2016 2018 2019 2020 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Ginkgo’s Foundry is scaling roughly 3x per year L A B OPER ATIONS: MEASURING WORK DONE ON THE PLATFORM STR AIN TESTS: MEASURING THE OUTPUT OF THE PLATFORM 1,000,000 10,000,000 1,000,000 100,000 100,000 3-4x annual increase pre-COVID 10,000 10,000 1,000 1,000 2-3x annual increase pre-COVID 100 100 10 2014 2015 2016 2017 2018 2019 2020 2021 2015 2016 2017 2018 2019 2020 2021 25 Daily Lab Operations Daily Strain Tests GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Ginkgo’s Foundry is scaling roughly 3x per year L A B OPER ATIONS: MEASURING WORK DONE ON THE PLATFORM STR AIN TESTS: MEASURING THE OUTPUT OF THE PLATFORM 1,000,000 10,000,000 1,000,000 100,000 100,000 3-4x annual increase pre-COVID 10,000 10,000 1,000 1,000 2-3x annual increase pre-COVID 100 100 10 2014 2015 2016 2017 2018 2019 2020 2021 2015 2016 2017 2018 2019 2020 2021 25 Daily Lab Operations Daily Strain Tests GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Unit costs to program cells have decreased by 50% per year $10,000 $1,000 FOUNDRY IS 5-10X CHEAPER THAN THE STATUS QUO ESTIMATED “BY HAND” COST $100 BY 2025, WE SHOULD BE TWO ORDERS OF MAGNITUDE MORE EFFICIENT THAN “BY HAND” COVID impact $10 $1 2015 2016 2017 2018 2019 2020 2021 2025 Note: Costs include all operational and R&D-related activities (i.e. both current programs and investments in future capacity) 26 Cost per Strain Test (rolling 3mo avg) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Unit costs to program cells have decreased by 50% per year $10,000 $1,000 FOUNDRY IS 5-10X CHEAPER THAN THE STATUS QUO ESTIMATED “BY HAND” COST $100 BY 2025, WE SHOULD BE TWO ORDERS OF MAGNITUDE MORE EFFICIENT THAN “BY HAND” COVID impact $10 $1 2015 2016 2017 2018 2019 2020 2021 2025 Note: Costs include all operational and R&D-related activities (i.e. both current programs and investments in future capacity) 26 Cost per Strain Test (rolling 3mo avg) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Codebase - Ginkgo’s scale data asset - is a source of long-term competitive advantage unique gene sequences pulled 3.4B+ from all public databases proprietary gene sequences acquired 440M And growing… codebase accumulates as we run new experiments in the foundry and build new: “Ginkgo will organize the world’s biological code and make it useful.” -GINKGO HE AD OF CODEBA SE, PATRICK BOYLE Organisms Genetic Code Biological Tools 27 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Codebase - Ginkgo’s scale data asset - is a source of long-term competitive advantage unique gene sequences pulled 3.4B+ from all public databases proprietary gene sequences acquired 440M And growing… codebase accumulates as we run new experiments in the foundry and build new: “Ginkgo will organize the world’s biological code and make it useful.” -GINKGO HE AD OF CODEBA SE, PATRICK BOYLE Organisms Genetic Code Biological Tools 27 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

(1) The $70B+ nitrogen-based fertilizer market accounts for approximately: 5% of global greenhouse We learn from wild (2) gas emissions biology to grow our 4% of global natural gas (3) Codebase production …and local environmental problems from runoff IMAGE CREDIT: KAREN INGRAM Some crops, such as legumes, have symbiotic microbes that convert atmospheric nitrogen into fertilizer, delivered straight to the plant’s roots… Joyn is working with Ginkgo to leverage this same Codebase for key cereal crops (1) Source: Grandview Research, as of 2018; imputed 2021 market shown (2) Source: US Environmental Protection Agency, as of 2018 (3) Source: SSLAC National Accelerator Laboratory (part of DEA), cited by Natural Gas Now, October 2014 28 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1(1) The $70B+ nitrogen-based fertilizer market accounts for approximately: 5% of global greenhouse We learn from wild (2) gas emissions biology to grow our 4% of global natural gas (3) Codebase production …and local environmental problems from runoff IMAGE CREDIT: KAREN INGRAM Some crops, such as legumes, have symbiotic microbes that convert atmospheric nitrogen into fertilizer, delivered straight to the plant’s roots… Joyn is working with Ginkgo to leverage this same Codebase for key cereal crops (1) Source: Grandview Research, as of 2018; imputed 2021 market shown (2) Source: US Environmental Protection Agency, as of 2018 (3) Source: SSLAC National Accelerator Laboratory (part of DEA), cited by Natural Gas Now, October 2014 28 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

IMAGE CREDIT: KAREN INGRAM We design codebase when C AT TLE (BEEF & DAIRY ) INDUS T RY: working on programs (1) $1 trillion global market (2) 9% of global greenhouse gas emissions Organisms like yeast (shown above) are the biological factories for producing a wide range of molecules (1) Source: imarc Group (February 2020) and Grandview Research (January 2019) (2) Source: Barclays Research (April 2019) 29 (1) Note targets are illustrative as Motif has not announced specific products. C OD EB A S E (1) EGG PROTEINS (1) ME AT PROTEINS (1) DAIRY PROTEINS GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1IMAGE CREDIT: KAREN INGRAM We design codebase when C AT TLE (BEEF & DAIRY ) INDUS T RY: working on programs (1) $1 trillion global market (2) 9% of global greenhouse gas emissions Organisms like yeast (shown above) are the biological factories for producing a wide range of molecules (1) Source: imarc Group (February 2020) and Grandview Research (January 2019) (2) Source: Barclays Research (April 2019) 29 (1) Note targets are illustrative as Motif has not announced specific products. C OD EB A S E (1) EGG PROTEINS (1) ME AT PROTEINS (1) DAIRY PROTEINS GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We re-use codebase across programs to improve outcomes and efficiency z C OD EB A S E The SAME YEAST used to generate proteins for food can produce proteins used in personal care products, such as collagen, elastin, and keratin Kalo 30 (1) Note targets are illustrative as Kalo has not announced specific products. GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We re-use codebase across programs to improve outcomes and efficiency z C OD EB A S E The SAME YEAST used to generate proteins for food can produce proteins used in personal care products, such as collagen, elastin, and keratin Kalo 30 (1) Note targets are illustrative as Kalo has not announced specific products. GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Ginkgo’s virtuous cycle drives platform growth 31 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Ginkgo’s virtuous cycle drives platform growth 31 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We believe Ginkgo’s ecosystem of services will make us the obvious partner in the enormous, and largely untapped, market for cell programming. 32 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We believe Ginkgo’s ecosystem of services will make us the obvious partner in the enormous, and largely untapped, market for cell programming. 32 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Each new cell program can accelerate adoption within new markets and lead to further sales with existing customers Ability to grow significantly within existing Early proof points within an industry customer accounts can lead to follow-on demand 12 10 (1) Major Program Minor Program Proof of Concept 8 6 [CONFIDENTIAL] 4 In advanced discussions with leading pharmaceutical contract manufacturer 2 [CONFIDENTIAL] Optimizing pDNA production 0 for another nucleic acid Year 1 Year 2 Year 3 Year 4 Year 5 vaccine company (1) Major programs typically incur well over $500K of annual R&D spending, minor programs are typically smaller add-on programs that have less than $500K of annual R&D spend, proof-of-concept programs are typically small programs that are often set up as a business development effort 33 # of Active Programs / Yr (Customer X) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Each new cell program can accelerate adoption within new markets and lead to further sales with existing customers Ability to grow significantly within existing Early proof points within an industry customer accounts can lead to follow-on demand 12 10 (1) Major Program Minor Program Proof of Concept 8 6 [CONFIDENTIAL] 4 In advanced discussions with leading pharmaceutical contract manufacturer 2 [CONFIDENTIAL] Optimizing pDNA production 0 for another nucleic acid Year 1 Year 2 Year 3 Year 4 Year 5 vaccine company (1) Major programs typically incur well over $500K of annual R&D spending, minor programs are typically smaller add-on programs that have less than $500K of annual R&D spend, proof-of-concept programs are typically small programs that are often set up as a business development effort 33 # of Active Programs / Yr (Customer X) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Strong 2021 sales pipeline with mix of new customers and expanded relationships [CONFIDENTIAL] Kalo Launched a new spin-out in personal New relationship with top 5 agchem New multi-product collaboration with top global care space, with strategic and financial company, focused on discovery and flavors & fragrances customer, building on investors development of crop protection agents successful historical program execution 100 95+ [key expansion areas] 6 7 major ~23 programs PROB. ADJ. 9 launched as of Crop 4/5/2021 protection Sugar reduction (2 new logos accounted for Renewable Recycling Protein 13 3 programs) feedstocks availability and Wastewater functionality remediation 50 13 Cell & gene Pulp/Paper therapy Skin 73 Antibodies microbiome 17 Nucleic acid Sustainability therapeutics Antibiotic manufacturing 15 0 Consumer & Technology Industrial Agriculture Pharma & Biotech Food & Nutrition Government & Defense Cumulative Historical + 2021 All Historical Programs 2021 34 Number of “Major” Pipeline Programs GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Strong 2021 sales pipeline with mix of new customers and expanded relationships [CONFIDENTIAL] Kalo Launched a new spin-out in personal New relationship with top 5 agchem New multi-product collaboration with top global care space, with strategic and financial company, focused on discovery and flavors & fragrances customer, building on investors development of crop protection agents successful historical program execution 100 95+ [key expansion areas] 6 7 major ~23 programs PROB. ADJ. 9 launched as of Crop 4/5/2021 protection Sugar reduction (2 new logos accounted for Renewable Recycling Protein 13 3 programs) feedstocks availability and Wastewater functionality remediation 50 13 Cell & gene Pulp/Paper therapy Skin 73 Antibodies microbiome 17 Nucleic acid Sustainability therapeutics Antibiotic manufacturing 15 0 Consumer & Technology Industrial Agriculture Pharma & Biotech Food & Nutrition Government & Defense Cumulative Historical + 2021 All Historical Programs 2021 34 Number of “Major” Pipeline Programs GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Our ecosystem will soon support hundreds of new cell programs a year 600 508 500 Self-Service Portals 400 Ecosystem Support 300 268 Still only 1-2% Platform Scaling of the market for 200 cell engineering (1) R&D services 136 Expand within Base 100 Leverage Proof Points 60 23 17 0 2020A 2021E 2022P 2023P 2024P 2025P (1) Source: Piper Sandler Research; assumes each program is approximately $2M per year of cell engineering spend and growth estimate of 0% and 20% 35 New Programs by Year GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Our ecosystem will soon support hundreds of new cell programs a year 600 508 500 Self-Service Portals 400 Ecosystem Support 300 268 Still only 1-2% Platform Scaling of the market for 200 cell engineering (1) R&D services 136 Expand within Base 100 Leverage Proof Points 60 23 17 0 2020A 2021E 2022P 2023P 2024P 2025P (1) Source: Piper Sandler Research; assumes each program is approximately $2M per year of cell engineering spend and growth estimate of 0% and 20% 35 New Programs by Year GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Ginkgo is creating the industry standard ecosystem Like other horizontal tech platforms, Ginkgo is building a strong developer community - wrapping services around the platform to drive industry growth and, ultimately, demand Launched Ginkgo Ferment, our annual conference, in 2018 VIEW KEYNOTE Other leading developer conferences 36 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Ginkgo is creating the industry standard ecosystem Like other horizontal tech platforms, Ginkgo is building a strong developer community - wrapping services around the platform to drive industry growth and, ultimately, demand Launched Ginkgo Ferment, our annual conference, in 2018 VIEW KEYNOTE Other leading developer conferences 36 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

REGULATORY We will be greatly expanding our ecosystem of services for cell programmers running on the Ginkgo platform Ginkgo annual developer Open-source conference and product Source of innovative bioengineering tools showcase technologies for industry partners: hub for investment, Help drive legislative acquisition, and partnership change for novel categories Mature manufacturing network across industries w/ clean tech-transfer protocols Help clients file patents / protect IP Biosecurity ESG Capital Access + Foundry Credits Ferment Consortium 37 COMMUNITY GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1REGULATORY We will be greatly expanding our ecosystem of services for cell programmers running on the Ginkgo platform Ginkgo annual developer Open-source conference and product Source of innovative bioengineering tools showcase technologies for industry partners: hub for investment, Help drive legislative acquisition, and partnership change for novel categories Mature manufacturing network across industries w/ clean tech-transfer protocols Help clients file patents / protect IP Biosecurity ESG Capital Access + Foundry Credits Ferment Consortium 37 COMMUNITY GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program adds predictable near-term revenue from usage fees and provides Ginkgo upside through value share. 38 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers Each new program adds predictable near-term revenue from usage fees and provides Ginkgo upside through value share. 38 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed programs Foundry Royalty Stream Equity Equity represents the risk- adjusted NPV of a potential royalty stream OR … … … … Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 0 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Highly predictable revenue Cash flows from value share are typically 100% contribution margin stream independent of as Ginkgo incurs minimal ongoing support or delivery costs program success The choice to structure downstream economics as royalties or equity is typically based on customer size Note: Illustrative economics; variation exists between programs 39 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Programs drive both predictable near-term revenues and long-term value creation with asymmetric upside potential Foundry Downstream Value Upfront payments to cover R&D Value sharing via customer equity and/or costs for customer programs royalties on completed programs Foundry Royalty Stream Equity Equity represents the risk- adjusted NPV of a potential royalty stream OR … … … … Yr 1 Yr 2 Yr 3 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Yr 0 Yr 4 Yr 5 Yr 6 Yr 7 Yr 8 Highly predictable revenue Cash flows from value share are typically 100% contribution margin stream independent of as Ginkgo incurs minimal ongoing support or delivery costs program success The choice to structure downstream economics as royalties or equity is typically based on customer size Note: Illustrative economics; variation exists between programs 39 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Program unit economics are strong and improving FOUNDRY USAGE FEES DOWNSTREAM VALUE CAPTURE Foundry Downstream Value Ginkgo receives downstream value in multiple forms. The equity Ginkgo has steadily increased the portion of program value per program provides context for the future value. R&D costs that are covered upfront by customers 54 120% 100% (2) Adj. for Free COVID Services Ginkgo will recognize royalty % Direct Cost Coverage Royalty / revenues over time as 100% Other 80% programs are completed These should be 20 and commercialized roughly equivalent in value over the long- 80% run, but royalties take 60% longer to materialize The current equity value of 60% our major programs is 40% over $500M (3) Equity 40% 34 …representing an average of 20% $15M per program 20% 0% 0% Major Programs 14-15 16-17 18-19 2020 (2017-2020) Year Deal Signed (1) Represents cumulative revenues from 2017-2020 for programs signed in the relevant year(s) divided by the total program expenses in 2017-2020 (2) Adjusts out expenses associated with programs Ginkgo performed under our free $25M commitment to COVID programs in spring 2020 40 (3) Includes one program for publicly-traded Cronos which is structured as a lump-sum equity payment upon delivery (1) % Cost Coverage of Programs Number of Major Programs Initiated GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Program unit economics are strong and improving FOUNDRY USAGE FEES DOWNSTREAM VALUE CAPTURE Foundry Downstream Value Ginkgo receives downstream value in multiple forms. The equity Ginkgo has steadily increased the portion of program value per program provides context for the future value. R&D costs that are covered upfront by customers 54 120% 100% (2) Adj. for Free COVID Services Ginkgo will recognize royalty % Direct Cost Coverage Royalty / revenues over time as 100% Other 80% programs are completed These should be 20 and commercialized roughly equivalent in value over the long- 80% run, but royalties take 60% longer to materialize The current equity value of 60% our major programs is 40% over $500M (3) Equity 40% 34 …representing an average of 20% $15M per program 20% 0% 0% Major Programs 14-15 16-17 18-19 2020 (2017-2020) Year Deal Signed (1) Represents cumulative revenues from 2017-2020 for programs signed in the relevant year(s) divided by the total program expenses in 2017-2020 (2) Adjusts out expenses associated with programs Ginkgo performed under our free $25M commitment to COVID programs in spring 2020 40 (3) Includes one program for publicly-traded Cronos which is structured as a lump-sum equity payment upon delivery (1) % Cost Coverage of Programs Number of Major Programs Initiated GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Growth in foundry revenues and new programs drives valuation Actuals Projections (1) ($M) 2018 2019 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $30 $54 $64 $100 $175 $341 $628 $1,099 % growth 78% 18% 57% 75% 95% 84% 75% memo: GAAP Adjustments $3 $0 ($4) GAAP Foundry Revenue $33 $54 $59 2017-2020 2021 2022 2023 2024 2025 20 34 # New Programs 23 60 136 268 508 Royalty Equity 54 % growth 157% 127% 97% 90% Increases if: p(success) increases, value of programs increases (2) Risk-Adjusted NPV / Program ~$15M Decreases if: lower take rates, value of programs decreases (2) # New Programs × NPV / Program NPV of New Programs Signed ~$500M (1) 2020A financials are draft audited and subject to final adjustments and line-item classifications 41 (2) Based on management estimate of the average current equity value of our cumulative major programs from 2017 to 2020 Key Program Metrics Key Foundry Metrics GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Growth in foundry revenues and new programs drives valuation Actuals Projections (1) ($M) 2018 2019 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $30 $54 $64 $100 $175 $341 $628 $1,099 % growth 78% 18% 57% 75% 95% 84% 75% memo: GAAP Adjustments $3 $0 ($4) GAAP Foundry Revenue $33 $54 $59 2017-2020 2021 2022 2023 2024 2025 20 34 # New Programs 23 60 136 268 508 Royalty Equity 54 % growth 157% 127% 97% 90% Increases if: p(success) increases, value of programs increases (2) Risk-Adjusted NPV / Program ~$15M Decreases if: lower take rates, value of programs decreases (2) # New Programs × NPV / Program NPV of New Programs Signed ~$500M (1) 2020A financials are draft audited and subject to final adjustments and line-item classifications 41 (2) Based on management estimate of the average current equity value of our cumulative major programs from 2017 to 2020 Key Program Metrics Key Foundry Metrics GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

These value streams support a strong valuation with meaningful upside potential FOUNDRY DOWNSTREAM VALUE BIOSECURITY 2021E Revenue (2024E) $628M 2025E New Programs 500+ $50M Revenue $12 Biosecurity may become a long- Rev. Growth (21-24E) 84% Annual Platform Value Add term revenue stream if = New Programs × NPV / Program $7.6B +/- $8 governments decide to invest in pandemic preparedness and $4B +/- Growth Life Science Tools Multiples $4 biosecurity more broadly $2B +/- $900M +/- $345M +/- 18.7x $0 Median 2024 2021 2022 2023 2024 2025 (1) Revenue Multiple OTHER Growth Tech Platform Multiples Discount rate applied to all annual NPVs and terminal value to 16.6x determine aggregate value today Median 2024 (1) Revenue Multiple For example, licensing and/or manufacturing of vaccinia capping enzyme (VCE) strain may yield significant near-term royalty Illustrative Valuation Illustrative Valuation revenues Higher Discount Rate vs. Peers: 20% 17.5x 2024E Revenue Conservative Terminal Growth Rate: 5% $11B $25B $628M 2024E Revenue No Improvements to Historical NPV/Program: $15M (1) Source: CapitalIQ, multiples reflect median of peer set as of 5/3/2021 42 VALUE TODAY + TERMINAL VALUE GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1These value streams support a strong valuation with meaningful upside potential FOUNDRY DOWNSTREAM VALUE BIOSECURITY 2021E Revenue (2024E) $628M 2025E New Programs 500+ $50M Revenue $12 Biosecurity may become a long- Rev. Growth (21-24E) 84% Annual Platform Value Add term revenue stream if = New Programs × NPV / Program $7.6B +/- $8 governments decide to invest in pandemic preparedness and $4B +/- Growth Life Science Tools Multiples $4 biosecurity more broadly $2B +/- $900M +/- $345M +/- 18.7x $0 Median 2024 2021 2022 2023 2024 2025 (1) Revenue Multiple OTHER Growth Tech Platform Multiples Discount rate applied to all annual NPVs and terminal value to 16.6x determine aggregate value today Median 2024 (1) Revenue Multiple For example, licensing and/or manufacturing of vaccinia capping enzyme (VCE) strain may yield significant near-term royalty Illustrative Valuation Illustrative Valuation revenues Higher Discount Rate vs. Peers: 20% 17.5x 2024E Revenue Conservative Terminal Growth Rate: 5% $11B $25B $628M 2024E Revenue No Improvements to Historical NPV/Program: $15M (1) Source: CapitalIQ, multiples reflect median of peer set as of 5/3/2021 42 VALUE TODAY + TERMINAL VALUE GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Leveraging capital to build the heart of the emerging cell programming ecosystem PL ATFORM & CAPACIT Y We are accelerating growth in capacity by integrating new technologies across the existing footprint, building new foundry space, and investing in software and automation to increase utilization. We strive to be the best place for the world’s top scientists, engineers, and software developers to build their careers ECOSYSTEM ACCELER ATION Capital availability centers Ginkgo at the heart of the next generation of programs by providing access to Foundry credits and capital STR ATEGIC ACQUISITIONS / PARTNERSHIPS Ginkgo has successfully acquired several technology and codebase assets. We plan to continue to selectively acquire assets in strategically important areas 43 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Leveraging capital to build the heart of the emerging cell programming ecosystem PL ATFORM & CAPACIT Y We are accelerating growth in capacity by integrating new technologies across the existing footprint, building new foundry space, and investing in software and automation to increase utilization. We strive to be the best place for the world’s top scientists, engineers, and software developers to build their careers ECOSYSTEM ACCELER ATION Capital availability centers Ginkgo at the heart of the next generation of programs by providing access to Foundry credits and capital STR ATEGIC ACQUISITIONS / PARTNERSHIPS Ginkgo has successfully acquired several technology and codebase assets. We plan to continue to selectively acquire assets in strategically important areas 43 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

The most powerful technologies require the most care Our culture is built on care, transparency, diversity, employee ownership and a deep, humble respect for biology. We take care in considering which programs we pursue We invest in our and which we do not, and explore the implications of biotechnologies through many forums, including our communities and their magazine: GROW biosecurity as well as robust ESG practices. READ MORE ABOUT: • The meaning of nature after biotechnology • The legacy of eugenics in beauty • The role of the philosopher in the life sciences • The potential for synthetic biology to save coral reefs • The impact of the pandemic on scientists and science 44 GI GI NK NKGO GO BI BI O O W W O O R R KK SS P I P E D E CK | AP R I L 2021 INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1The most powerful technologies require the most care Our culture is built on care, transparency, diversity, employee ownership and a deep, humble respect for biology. We take care in considering which programs we pursue We invest in our and which we do not, and explore the implications of biotechnologies through many forums, including our communities and their magazine: GROW biosecurity as well as robust ESG practices. READ MORE ABOUT: • The meaning of nature after biotechnology • The legacy of eugenics in beauty • The role of the philosopher in the life sciences • The potential for synthetic biology to save coral reefs • The impact of the pandemic on scientists and science 44 GI GI NK NKGO GO BI BI O O W W O O R R KK SS P I P E D E CK | AP R I L 2021 INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We hope… …that when technology meets biology, life finds a way. 45 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1We believe… 1 2 3 4 Programming cells Ginkgo’s platform Ginkgo is becoming Our value increases will be as impactful improves with scale the industry standard with each new program as programming added to the platform computers We hope… …that when technology meets biology, life finds a way. 45 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

APPENDIX 46APPENDIX 46

Attractive entry valuation vs. peers CY 2021-24E Revenue CAGR (2) (1) Median: 32% Median: 33% 84% 54% 53% 38% 36% 32% 33% 32% 29% 28% 14% NM (4) Adjusted for CY 2024 TEV / Revenue value share Median: 18.7x Median: 16.6x 27.2x (1) 24.1x 21.6x 20.9x 19.2x 18.9x 16.6x 16.5x 15.5x 13.7x (3) 12.6x 10.8x 10.1x (4) (5) CY 2024 Growth Adjusted TEV / Revenue Adjusted for 1.15x value share (2) Median: 0.48x Median: 0.42x 0.75x 0.68x 0.66x 0.48x 0.46x 0.42x (1) 0.36x 0.33x 0.29x (3) 0.19x 0.11x NM (4) Source: Company filings and Capital IQ as of 5/3/2021 4. Veeva CY2024 figures excludes SVB Leerink estimates 1. Includes Foundry Billable Revenues only 5. Calculated as CY 2024 revenue multiple divided by ’21-’24 revenue CAGR 47 2. Excludes AbCellera Life Science Leaders Software and Data 3. Includes Foundry Billable Revenues and one-tenth of cumulative 2017-2024 NPV from New Programs GI NKGO BI O W O R K S P I P E D E CK | AP R I L 2021Attractive entry valuation vs. peers CY 2021-24E Revenue CAGR (2) (1) Median: 32% Median: 33% 84% 54% 53% 38% 36% 32% 33% 32% 29% 28% 14% NM (4) Adjusted for CY 2024 TEV / Revenue value share Median: 18.7x Median: 16.6x 27.2x (1) 24.1x 21.6x 20.9x 19.2x 18.9x 16.6x 16.5x 15.5x 13.7x (3) 12.6x 10.8x 10.1x (4) (5) CY 2024 Growth Adjusted TEV / Revenue Adjusted for 1.15x value share (2) Median: 0.48x Median: 0.42x 0.75x 0.68x 0.66x 0.48x 0.46x 0.42x (1) 0.36x 0.33x 0.29x (3) 0.19x 0.11x NM (4) Source: Company filings and Capital IQ as of 5/3/2021 4. Veeva CY2024 figures excludes SVB Leerink estimates 1. Includes Foundry Billable Revenues only 5. Calculated as CY 2024 revenue multiple divided by ’21-’24 revenue CAGR 47 2. Excludes AbCellera Life Science Leaders Software and Data 3. Includes Foundry Billable Revenues and one-tenth of cumulative 2017-2024 NPV from New Programs GI NKGO BI O W O R K S P I P E D E CK | AP R I L 2021

Projected P&L (1) ($M) 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $64 $100 $175 $341 $628 $1,099 % growth 18% 57% 75% 95% 84% 75% memo: GAAP Adjustments ($4) GAAP adjustments not projected Foundry Revenue (GAAP) $59 $100 $175 $341 $628 $1,099 Emerging business, projections not provided (+) Biosecurity $17 $50 Total GAAP Revenue $77 $150 $175 $341 $628 $1,099 (2) Adjusted EBITDA ($123) ($157) ($156) ($136) ($47) $166 (3) Capital Expenditures ($72) ($66) ($118) ($146) ($193) ($234) (1) 2020A financials are draft audited and subject to final adjustments and line item classifications (2) See slide 50 for a reconciliation of Net Income to Adjusted EBITDA for historical periods presented (3) 2020 CapEx of $72M includes $14M of CapEx that is included in Accounts Payable and Accrued Expenses at 12/31/2020 48 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Projected P&L (1) ($M) 2020 2021 2022 2023 2024 2025 Foundry Billable Revenue $64 $100 $175 $341 $628 $1,099 % growth 18% 57% 75% 95% 84% 75% memo: GAAP Adjustments ($4) GAAP adjustments not projected Foundry Revenue (GAAP) $59 $100 $175 $341 $628 $1,099 Emerging business, projections not provided (+) Biosecurity $17 $50 Total GAAP Revenue $77 $150 $175 $341 $628 $1,099 (2) Adjusted EBITDA ($123) ($157) ($156) ($136) ($47) $166 (3) Capital Expenditures ($72) ($66) ($118) ($146) ($193) ($234) (1) 2020A financials are draft audited and subject to final adjustments and line item classifications (2) See slide 50 for a reconciliation of Net Income to Adjusted EBITDA for historical periods presented (3) 2020 CapEx of $72M includes $14M of CapEx that is included in Accounts Payable and Accrued Expenses at 12/31/2020 48 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Summary of Historical Income Statements Year Ended December 31, (1) ($ in M) 2019A 2020A (2) Revenue $54.2 $76.7 % Growth 66% 41% Cost of Biosecurity product revenue 0.0 6.7 Cost of Biosecurity service revenue 0.0 8.9 Research & development 96.3 159.8 General & administrative 29.5 38.3 Total Operating Expenses $125.8 $213.7 Loss from Operations ($71.6) ($137.0) Net interest income 3.3 0.2 Loss on equity method investments (46.9) (3.1) Loss on investments (7.8) (1.1) Other income, net 3.2 16.1 Loss before provision for income taxes ($119.8) ($124.8) Provision for income taxes 0.0 1.9 Net Loss and Comprehensive Loss ($119.9) ($126.7) (Loss) / Income attributable to NCI (0.5) (0.1) Net Loss Attributable to Ginkgo ($119.3) ($126.6) (1) 2020A draft audited financials subject to final adjustments and line item classifications. 49 (2) GAAP revenue includes transactions with platform ventures (Motif, Joyn, and Allonnia) as well as other structured partnerships (Genomatica and Synlogic) where, as part of these transactions, Ginkgo received an equity interest in such entities. These equity investees are considered related parties due to the equity position Ginkgo received in these entities and generated total revenues of $42.5M and $35.3M in 2020 and 2019, respectively. GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Summary of Historical Income Statements Year Ended December 31, (1) ($ in M) 2019A 2020A (2) Revenue $54.2 $76.7 % Growth 66% 41% Cost of Biosecurity product revenue 0.0 6.7 Cost of Biosecurity service revenue 0.0 8.9 Research & development 96.3 159.8 General & administrative 29.5 38.3 Total Operating Expenses $125.8 $213.7 Loss from Operations ($71.6) ($137.0) Net interest income 3.3 0.2 Loss on equity method investments (46.9) (3.1) Loss on investments (7.8) (1.1) Other income, net 3.2 16.1 Loss before provision for income taxes ($119.8) ($124.8) Provision for income taxes 0.0 1.9 Net Loss and Comprehensive Loss ($119.9) ($126.7) (Loss) / Income attributable to NCI (0.5) (0.1) Net Loss Attributable to Ginkgo ($119.3) ($126.6) (1) 2020A draft audited financials subject to final adjustments and line item classifications. 49 (2) GAAP revenue includes transactions with platform ventures (Motif, Joyn, and Allonnia) as well as other structured partnerships (Genomatica and Synlogic) where, as part of these transactions, Ginkgo received an equity interest in such entities. These equity investees are considered related parties due to the equity position Ginkgo received in these entities and generated total revenues of $42.5M and $35.3M in 2020 and 2019, respectively. GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Historical Net Loss to Adjusted EBITDA Reconciliation Year Ended December 31, (1) ($ in M) 2019A 2020A Net Loss Attributable to Ginkgo ($119.3) ($126.6) Net interest income (3.3) ($0.2) Depreciation and amortization 10.8 $13.9 Loss attributable to equity method investments, net of NCI 46.4 $2.9 Loss on investments 7.8 $1.1 Provision for income taxes 0.0 $1.9 Stock compensation expense 0.8 $0.5 Other non-recurring transactions (3.1) ($14.9) Adjusted EBITDA ($60.0) ($121.4) (1) 2020A draft audited financials subject to final adjustments and line item classifications. 50 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Historical Net Loss to Adjusted EBITDA Reconciliation Year Ended December 31, (1) ($ in M) 2019A 2020A Net Loss Attributable to Ginkgo ($119.3) ($126.6) Net interest income (3.3) ($0.2) Depreciation and amortization 10.8 $13.9 Loss attributable to equity method investments, net of NCI 46.4 $2.9 Loss on investments 7.8 $1.1 Provision for income taxes 0.0 $1.9 Stock compensation expense 0.8 $0.5 Other non-recurring transactions (3.1) ($14.9) Adjusted EBITDA ($60.0) ($121.4) (1) 2020A draft audited financials subject to final adjustments and line item classifications. 50 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Historical Foundry GAAP to Billable Revenue Reconciliation Year Ended December 31, (1) ($ in M) 2019A 2020A Foundry Revenue (GAAP) $54.2 $59.2 % Growth 66% 9% (2) 2.7 13.6 Synlogic Adjustment (3) (3.2) (9.3) Equity Investee Adjustment Total Adjustments ($0.4) $4.3 Foundry Billable Revenue $53.7 $63.5 % Growth 78% 18% (1) 2020A draft audited financials subject to final adjustments and line item classifications. (2) Adjustment to increase Foundry Billable Revenue for the value of services provided to Synlogic which are not reported under GAAP due to an attribution of the amount paid above fair value for the Synlogic equity to the services prepayment at the time of the investment. (3) Adjustment to decrease Foundry Billable Revenue for non-cash revenue that is recognized under GAAP to account for equity received at the time of inception of the collaboration. 51 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Historical Foundry GAAP to Billable Revenue Reconciliation Year Ended December 31, (1) ($ in M) 2019A 2020A Foundry Revenue (GAAP) $54.2 $59.2 % Growth 66% 9% (2) 2.7 13.6 Synlogic Adjustment (3) (3.2) (9.3) Equity Investee Adjustment Total Adjustments ($0.4) $4.3 Foundry Billable Revenue $53.7 $63.5 % Growth 78% 18% (1) 2020A draft audited financials subject to final adjustments and line item classifications. (2) Adjustment to increase Foundry Billable Revenue for the value of services provided to Synlogic which are not reported under GAAP due to an attribution of the amount paid above fair value for the Synlogic equity to the services prepayment at the time of the investment. (3) Adjustment to decrease Foundry Billable Revenue for non-cash revenue that is recognized under GAAP to account for equity received at the time of inception of the collaboration. 51 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

ADDITIONAL CASE STUDIES 52ADDITIONAL CASE STUDIES 52

CASE STUDY 1 A leading company for production of natural Producing cultured ingredients was looking for cost-saving opportunities. Ginkgo identified a plan to ingredients at scale fine-tune existing pathways in yeast to produce multiple flavors more efficiently, then optimized the conditions for scale-up. Ginkgo’s Result Ginkgo’s Foundry utilizes the ambr250 disposable reactor system to inform design of experiments and reduce operating costs via automation, Client’s Goal allowing us to run hundreds of bioreactors simultaneously. Using the information generated to rationally improve the strain and fermentation process conditions, Ginkgo exceeded the client’s desired product titer by 50%. Apr. '15 Sep. '15 Dec. '15 Mar. '16 Nov. '16 Feb. '17 53 Product Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 1 A leading company for production of natural Producing cultured ingredients was looking for cost-saving opportunities. Ginkgo identified a plan to ingredients at scale fine-tune existing pathways in yeast to produce multiple flavors more efficiently, then optimized the conditions for scale-up. Ginkgo’s Result Ginkgo’s Foundry utilizes the ambr250 disposable reactor system to inform design of experiments and reduce operating costs via automation, Client’s Goal allowing us to run hundreds of bioreactors simultaneously. Using the information generated to rationally improve the strain and fermentation process conditions, Ginkgo exceeded the client’s desired product titer by 50%. Apr. '15 Sep. '15 Dec. '15 Mar. '16 Nov. '16 Feb. '17 53 Product Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 1 Producing cultured ingredients at scale Ginkgo ambr250 EOF Optimal Process (average of 20 runs) Ginkgo’s system enables high Ginkgo ambr250 EOF throughput screening without Deployed Process (increased process robustness) compromising quality of data. The conditions optimized at a Pilot 250L volume of 250 mL were effectively translated into pilot Commercial 50,000L and commercial scale, and the cultured ingredients reached commercial production with Elapsed Fermentation Time (h) our manufacturing partners. FERMIC ME XICO 54 Product Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 1 Producing cultured ingredients at scale Ginkgo ambr250 EOF Optimal Process (average of 20 runs) Ginkgo’s system enables high Ginkgo ambr250 EOF throughput screening without Deployed Process (increased process robustness) compromising quality of data. The conditions optimized at a Pilot 250L volume of 250 mL were effectively translated into pilot Commercial 50,000L and commercial scale, and the cultured ingredients reached commercial production with Elapsed Fermentation Time (h) our manufacturing partners. FERMIC ME XICO 54 Product Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 2 6 GINKGO APPROACH 5 LED TO DISCOVERY OF Using biomining 4 A BETTER PROTEIN techniques to 3 recycle compounds 2 1 Some of the compounds in objects we 0 use everyday are difficult to recycle. Previous Best in Market Best Ginkgo Identified By identifying proteins that selectively Protein Protein bind to these compounds, we can The Ginkgo Foundry allows us to synthesize, screen, and test for recover them from post-manufacturing these proteins at a scale unmatched by others. In our primary or recycled material, moving us closer screen, we screened over 1000 unique proteins, testing a total of to a circular economy. over 10,000 samples. From that screen, we identified the best hits. In our secondary screen, we discovered a protein that binds hard-to-recycle compounds 5X more than previously seen in the market. 55 Relative Signal of Bound Compounds GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 2 6 GINKGO APPROACH 5 LED TO DISCOVERY OF Using biomining 4 A BETTER PROTEIN techniques to 3 recycle compounds 2 1 Some of the compounds in objects we 0 use everyday are difficult to recycle. Previous Best in Market Best Ginkgo Identified By identifying proteins that selectively Protein Protein bind to these compounds, we can The Ginkgo Foundry allows us to synthesize, screen, and test for recover them from post-manufacturing these proteins at a scale unmatched by others. In our primary or recycled material, moving us closer screen, we screened over 1000 unique proteins, testing a total of to a circular economy. over 10,000 samples. From that screen, we identified the best hits. In our secondary screen, we discovered a protein that binds hard-to-recycle compounds 5X more than previously seen in the market. 55 Relative Signal of Bound Compounds GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 3 Foundries allow us to explore a broader range of biological diversity Enzymes come from a wide variety of source organisms Powered by gigabase-scale DNA synthesis, Ginkgo explores biodiversity to identify novel or improved enzyme activities and design pathways programmatically Clusters of enzymes without any Cluster containing best- existing annotation, which Ginkgo documented enzymes can investigate further for this class 56 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 3 Foundries allow us to explore a broader range of biological diversity Enzymes come from a wide variety of source organisms Powered by gigabase-scale DNA synthesis, Ginkgo explores biodiversity to identify novel or improved enzyme activities and design pathways programmatically Clusters of enzymes without any Cluster containing best- existing annotation, which Ginkgo documented enzymes can investigate further for this class 56 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 4 Approach: By capitalizing on the capacity of the Foundry, Ginkgo could screen a large number of pathway architectures to construct the pathway. Pathway design promoters enzyme 1 enzyme 2 enzyme 3 for a complex x 8 x 4 9 x 4 metabolic pathway Situation: A client wished to decrease = 1,152 synthons their reliance on expensive feedstocks and replace it with a low-cost 2,719 PATHWAYS EVALUATED substrate that the strain could not naturally assimilate. Ginkgo engineered a strain to assimilate the low-cost substrate, while maintaining 7,717 ENZYMES SCREENED productivity and yield. 109,000,000 BASE PAIRS OF SYNTHETIC DNA DESIGNED 57 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 4 Approach: By capitalizing on the capacity of the Foundry, Ginkgo could screen a large number of pathway architectures to construct the pathway. Pathway design promoters enzyme 1 enzyme 2 enzyme 3 for a complex x 8 x 4 9 x 4 metabolic pathway Situation: A client wished to decrease = 1,152 synthons their reliance on expensive feedstocks and replace it with a low-cost 2,719 PATHWAYS EVALUATED substrate that the strain could not naturally assimilate. Ginkgo engineered a strain to assimilate the low-cost substrate, while maintaining 7,717 ENZYMES SCREENED productivity and yield. 109,000,000 BASE PAIRS OF SYNTHETIC DNA DESIGNED 57 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 4 30 Pathway design for a complex 22.5 metabolic pathway 15 The strains transferred to the customer could assimilate the 7.5 new feedstock 25 times more than the original strain, achieving the target. 0 1 2 3 4 5 6 Results over time à 58 Assimilation of new feedstock (%) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 4 30 Pathway design for a complex 22.5 metabolic pathway 15 The strains transferred to the customer could assimilate the 7.5 new feedstock 25 times more than the original strain, achieving the target. 0 1 2 3 4 5 6 Results over time à 58 Assimilation of new feedstock (%) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 5 Making more sustainable foods with kilogram-scale protein production Situation: Ginkgo partnered with Motif FoodWorks to develop commercial yeast strains and processes for protein production at the kilogram scale. The target protein would be used to make foods more delicious and sustainable. 59 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 5 Making more sustainable foods with kilogram-scale protein production Situation: Ginkgo partnered with Motif FoodWorks to develop commercial yeast strains and processes for protein production at the kilogram scale. The target protein would be used to make foods more delicious and sustainable. 59 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 5 Making more sustainable foods % with kilogram-scale protein production 303 300 IMPROVEMENT OVER PROTEINS UNMODIFIED Discovery: Leveraging our Codebase and Foundry, we SOURCED STRAINS identified and screened hundreds of distinct candidate proteins. Top performers were engineered with novel expression systems to maximize protein expression. In just 1 year, 6 prototype strains were developed, and product samples were produced for benchmarking and early application testing. Improved variants were designed, built and validated over the next 9 months. Q4 Q1 Q2 Q3 1 YEAR LATER ITERATIVE STRAIN IDENTIFY POTENTIAL SCREEN FOR BEST STRAIN ENGINEERING & PROTOTYPE STRAINS CONSTRUCTION & TESTING PROTEINS CANDIDATE PROTEIN PATHWAY BALANCING READY Sequence Similarity Network PROTOTYPE Strain Strain Strain 60 Percent Improvement over Seed Protein Percent Improvement over Unmodified Strains Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 5 Making more sustainable foods % with kilogram-scale protein production 303 300 IMPROVEMENT OVER PROTEINS UNMODIFIED Discovery: Leveraging our Codebase and Foundry, we SOURCED STRAINS identified and screened hundreds of distinct candidate proteins. Top performers were engineered with novel expression systems to maximize protein expression. In just 1 year, 6 prototype strains were developed, and product samples were produced for benchmarking and early application testing. Improved variants were designed, built and validated over the next 9 months. Q4 Q1 Q2 Q3 1 YEAR LATER ITERATIVE STRAIN IDENTIFY POTENTIAL SCREEN FOR BEST STRAIN ENGINEERING & PROTOTYPE STRAINS CONSTRUCTION & TESTING PROTEINS CANDIDATE PROTEIN PATHWAY BALANCING READY Sequence Similarity Network PROTOTYPE Strain Strain Strain 60 Percent Improvement over Seed Protein Percent Improvement over Unmodified Strains Titer (g/L) GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 5 Making more sustainable foods with kilogram-scale protein production Scale: Within 2 years, Ginkgo developed commercial strains from scratch, as well as fermentation and downstream purification processes that are now being used at kilogram-scale, with a total projected 3 years time-to-market for the final food ingredient product. The strain’s performance exceeded Motif’s specifications by >70%. Further, we identified a set of novel protein expression systems that exceed performance of best-in-class systems by 5-20 fold, thereby increasing productivity, reducing cost, and improving scalability over additional rounds of engineering. OUR FOUNDRY can be easily repurposed to create additional food products, thereby shortening the time-to-market for each new product, and helping us forge the future of more sustainable and accessible foods. 61 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 5 Making more sustainable foods with kilogram-scale protein production Scale: Within 2 years, Ginkgo developed commercial strains from scratch, as well as fermentation and downstream purification processes that are now being used at kilogram-scale, with a total projected 3 years time-to-market for the final food ingredient product. The strain’s performance exceeded Motif’s specifications by >70%. Further, we identified a set of novel protein expression systems that exceed performance of best-in-class systems by 5-20 fold, thereby increasing productivity, reducing cost, and improving scalability over additional rounds of engineering. OUR FOUNDRY can be easily repurposed to create additional food products, thereby shortening the time-to-market for each new product, and helping us forge the future of more sustainable and accessible foods. 61 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 6 Producing cultured cannabinoids Plants like cannabis hold many unique compounds that can have important health benefits, but many of those compounds are impractical and expensive to extract and purify. With our landmark partnership with Cronos Group, we are working to produce eight target cultured cannabinoids at high quality and purity. To scale manufacturing of products from this partnership, our deployment team supported the evaluation and build-out of an 84,000 square foot fermentation facility in Winnipeg, Canada. 62 IMAGE CREDIT: KAREN INGRAM GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 6 Producing cultured cannabinoids Plants like cannabis hold many unique compounds that can have important health benefits, but many of those compounds are impractical and expensive to extract and purify. With our landmark partnership with Cronos Group, we are working to produce eight target cultured cannabinoids at high quality and purity. To scale manufacturing of products from this partnership, our deployment team supported the evaluation and build-out of an 84,000 square foot fermentation facility in Winnipeg, Canada. 62 IMAGE CREDIT: KAREN INGRAM GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 7 Engineering living Situation: For approximately 2 years, Synlogic had been prototyping a strain and pathway to medicines consume leucine, but initial modeling suggested that more activity was needed for target therapeutic effect. Approach: To optimize the complex pathway to increase consumption, Ginkgo sourced, synthesized and screened 3,600 enzymes to identify the best performing enzymes. Using the best enzymes, we designed and screened a combinatorial library of 350 pathways. HIGH THROUGHPUT SCREENING OF PATHWAYS + PERFORMANCE Presented at SEED June 2019 63 IMAGE CREDIT: KAREN INGRAM GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 7 Engineering living Situation: For approximately 2 years, Synlogic had been prototyping a strain and pathway to medicines consume leucine, but initial modeling suggested that more activity was needed for target therapeutic effect. Approach: To optimize the complex pathway to increase consumption, Ginkgo sourced, synthesized and screened 3,600 enzymes to identify the best performing enzymes. Using the best enzymes, we designed and screened a combinatorial library of 350 pathways. HIGH THROUGHPUT SCREENING OF PATHWAYS + PERFORMANCE Presented at SEED June 2019 63 IMAGE CREDIT: KAREN INGRAM GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

Enzyme 2 Enzyme 3 Enzyme 1 CASE STUDY Leucine Byproduct 7 Rapid pathway development 3-step leucine consumption pathway PARENT PATHWAY PERFORMANCE High-throughput screening of pathways using targeted metabolomics Metagenomic enzyme High throughput screening Use top enzymes to design sourcing and synthesis of >1200 enzymes per class combinatorial library of Presented at SEED June 2019 350 pathways 64 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1Enzyme 2 Enzyme 3 Enzyme 1 CASE STUDY Leucine Byproduct 7 Rapid pathway development 3-step leucine consumption pathway PARENT PATHWAY PERFORMANCE High-throughput screening of pathways using targeted metabolomics Metagenomic enzyme High throughput screening Use top enzymes to design sourcing and synthesis of >1200 enzymes per class combinatorial library of Presented at SEED June 2019 350 pathways 64 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 7 Engineering living medicines With a simpler biological design, Ginkgo improved the Synlogic strain’s ability to consume leucine by nearly 7x. Furthermore, the Synlogic-Ginkgo optimized strain SYN5941 lowers protein-induced leucine consumption in non-human primates. Presented at SEED June 2019 65 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 7 Engineering living medicines With a simpler biological design, Ginkgo improved the Synlogic strain’s ability to consume leucine by nearly 7x. Furthermore, the Synlogic-Ginkgo optimized strain SYN5941 lowers protein-induced leucine consumption in non-human primates. Presented at SEED June 2019 65 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1

CASE STUDY 8 Leveraging scale to optimize enzyme activity enzyme activity C A S E S T UD Y Our client was seeking an enzyme that could New IP enhance an underperforming, in-house program in the industrials space Ginkgo created a diverse library of 1,700+ enzyme variants, informed by our Codebase I M P A C T Our program reduced enzyme requirement by Client’s Prior Best 80% and improved performance Without Ginkgo’s capacity for testing or broad Codebase, the best enzyme wouldn’t likely have been discovered or selected for testing enzymes tested 66 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1CASE STUDY 8 Leveraging scale to optimize enzyme activity enzyme activity C A S E S T UD Y Our client was seeking an enzyme that could New IP enhance an underperforming, in-house program in the industrials space Ginkgo created a diverse library of 1,700+ enzyme variants, informed by our Codebase I M P A C T Our program reduced enzyme requirement by Client’s Prior Best 80% and improved performance Without Ginkgo’s capacity for testing or broad Codebase, the best enzyme wouldn’t likely have been discovered or selected for testing enzymes tested 66 GI NKGO BI O W O R K S INV E S T O R P R E S E N T A T IO N| M A Y 2 0 2 1